GlassScriptPhysician profile
Jeffrey Thomas Omer
NPI 1821062605
$8,428.40
in general payments reported to CMS, 2019-2025
39 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $902 · 2021: $1,525 · 2022: $1,414 · 2023: $1,632 · 2024: $1,555 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,262 · Education: $4.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,261.56 |
| Education | $4.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,100.69 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,032.23 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $894.73 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $860.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $644.30 | 2020-2021 | |
| Lilly USA, LLC | $609.85 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Phathom Pharmaceuticals, INC. | $508.51 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $504.45 | 2020-2025 | Nexletol |
| Pfizer INC. | $477.10 | 2019-2025 | |
| Glaxosmithkline, LLC. | $323.75 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $217.80 | 2022-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $134.57 | 2021-2025 | |
| Exact Sciences Corporation | $132.28 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $87.51 | 2020-2025 | |
| Axsome Therapeutics, INC. | $78.73 | 2023-2024 | Auvelity |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Omer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.